The weight loss drug revolution just got a price tag that actually makes sense. HHS has announced the Medicare GLP-1 Bridge pilot program, starting July 1 and running through December 31, 2027, that caps the cost of Wegovy, Foundayo, and Zepbound KwikPens at $50 per month for eligible Medicare Part D enrollees. An estimated 14 million recipients could qualify — representing the federal government's boldest move yet to make these blockbuster drugs...